Month: January 2019

Labcyte Round

Labcyte Sold to Beckman Coulter.

Dublin, Ireland.  30 January 2019.  Seroba portfolio company, Labcyte, has been acquired by Beckman Coulter Life Sciences, part of the larger Danaher Corporation which generates approximately $6.5 billion in annual revenue. Labcyte is best known for its Echo® acoustic droplet ejection technology, which uses sound waves to transfer tiny amounts of liquid with unequalled speed …

Labcyte Sold to Beckman Coulter. Read More »

PQ Bypass

PQ Bypass Announces $60M Financing.

Ireland and California, USA.  January 08, 2019.  Seroba’s portfolio company, PQ Bypass, Inc., a medical device company dedicated to advancing treatment options for patients with peripheral arterial disease (PAD), has entered into an agreement that provides for up to an aggregate of $60 million in equity financing, led by Deerfield Management. Joining the round are …

PQ Bypass Announces $60M Financing. Read More »

Atlantic Innove

Atlantic Therapeutics Raise €28M in Series B Funding.

Galway, Ireland.  7 January 2019.  Atlantic Therapeutics, the medical technology company developing garment-based pelvic floor muscle strengthening and nerve stimulation devices treating the cause of bladder leaks, has announced that it has closed €28 million in Series B funding to continue its rapid growth trajectory. Having recently gained FDA clearance for its INNOVO® therapy device, …

Atlantic Therapeutics Raise €28M in Series B Funding. Read More »

Quanta Sc

Quanta Appoints New Chief Medical Officer

Alcester, UK, 4 Jan 2019: Seroba portfolio company, Quanta Dialysis Technologies Ltd (“Quanta” or the “Company”), a medical device company providing innovative haemodialysis solutions for clinic and home settings, today announced the Company has appointed Dr Paul Komenda as CMO. Quanta has also announced that it will be at the JP Morgan Healthcare Conference in …

Quanta Appoints New Chief Medical Officer Read More »

We use cookies and analytics to improve your online experience and to help us to understand where our audience is and how they reach us, as well as to understand what topics and site features are of greatest interest.  To find out more, please read our Privacy Policy. By clicking on the Accept button, you consent to our use of cookies and browsing analytics.

Scroll to Top